Literature DB >> 18037158

Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.

Markéta Tomsová1, Bohuslav Melichar, Iva Sedláková, Ivo Steiner.   

Abstract

OBJECTIVE: Epithelial ovarian cancer (EOC) is the most common cause of death among gynecological malignancies in Europe and North America. Although the presence of tumor-infiltrating mononuclear cells has been documented in EOC, the association of tumor-infiltrating mononuclear cells with clinical outcome remains controversial. The aim of the present study was to investigate the prognostic significance of CD3+ tumor-infiltrating T lymphocytes (TIL) on overall survival of EOC patients.
METHODS: We evaluated retrospectively by immunohistochemistry the distribution of CD3+ TIL in tumor specimens of 116 EOC patients. The expression of estrogen and progesterone receptors, Ki-67, DNA topoisomerase IIalpha, p21, p53, HER-2/neu, bax and bcl-2 was also evaluated by immunohistochemistry. The prognostic significance of CD3+ TIL and other immunohistochemical and clinical parameters was evaluated with log-rank test. Multivariate analysis was performed using the Cox regression.
RESULTS: CD3+ TIL were observed in all tumor samples, both in cancer stroma and within cancer epithelium (intraepithelial TIL). The median counts of stromal TIL and intraepithelial TIL were 338 lymphocytes/mm2 (range 81-2094 lymphocytes/mm2) and 125 lymphocytes/mm2 (range 7-481 lymphocytes/mm2), respectively. In univariate analysis, age, stage, grade, presence of residual tumor, expression of progesterone receptors, Ki-67, DNA topoisomerase IIalpha and intraepithelial CD3+ TIL count were significant predictors of overall survival. On multivariate analysis, only the presence of residual tumor, stage, expression of progesterone receptors and intraepithelial CD3+ TIL count were found to be significant independent predictors of overall survival.
CONCLUSION: Present data indicate that the intraepithelial CD3+ TIL count is a significant prognostic factor in EOC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18037158     DOI: 10.1016/j.ygyno.2007.10.016

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  91 in total

1.  Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.

Authors:  Eiman Adel Hasby
Journal:  Pathol Oncol Res       Date:  2011-12-08       Impact factor: 3.201

2.  Lymphopenia after induction chemotherapy correlates with incomplete surgical resection in patients with advanced ovarian cancer.

Authors:  Yasunori Yoshino; Ayumi Taguchi; Maki Takao; Tomoko Kashiyama; Akiko Furusawa; Masaya Uno; Satoshi Okada; Nao Kino; Toshiharu Yasugi
Journal:  Int J Clin Oncol       Date:  2018-11-30       Impact factor: 3.402

Review 3.  Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.

Authors:  Vishal Jindal; Ena Arora; Sorab Gupta; Amos Lal; Muhammad Masab; Rashmika Potdar
Journal:  Med Oncol       Date:  2018-04-12       Impact factor: 3.064

Review 4.  Aiming to immune elimination of ovarian cancer stem cells.

Authors:  Jiabo Di; Tjitske Duiveman-de Boer; Carl G Figdor; Ruurd Torensma
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

5.  Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer.

Authors:  Yeonjoo Choi; Jin Won Kim; Kyung Han Nam; Song-Hee Han; Ji-Won Kim; Sang-Hoon Ahn; Do Joong Park; Keun-Wook Lee; Hye Seung Lee; Hyung-Ho Kim
Journal:  Gastric Cancer       Date:  2016-09-24       Impact factor: 7.370

6.  Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer.

Authors:  Ravi A Madan; Thomas Schwaab; James L Gulley
Journal:  J Natl Compr Canc Netw       Date:  2012-12-01       Impact factor: 11.908

Review 7.  The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Authors:  Lana E Kandalaft; Nathan Singh; John B Liao; Andrea Facciabene; Jonathan S Berek; Daniel J Powell; George Coukos
Journal:  Gynecol Oncol       Date:  2009-12-02       Impact factor: 5.482

8.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

9.  Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes.

Authors:  M Stumpf; A Hasenburg; M-O Riener; U Jütting; C Wang; Y Shen; M Orlowska-Volk; P Fisch; Z Wang; G Gitsch; M Werner; S Lassmann
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

10.  Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.

Authors:  P de Graeff; A P G Crijns; S de Jong; M Boezen; W J Post; E G E de Vries; A G J van der Zee; G H de Bock
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.